Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab, dexamethasone, and lenalidomide induction with randomised lenalidomide maintenance in high-risk CLL
ISRCTN40303610Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of alemtuzumab, dexamethasone and lenalidomide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by University of Liverpool. Primary endpoints: Complete response and Complete response with incomplete blood count recovery. Started Sep 2011; status: completed.
02
Drugs
alemtuzumabdexamethasonelenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN40303610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40303610.